Obesity drugs

Search documents
X @Bloomberg
Bloomberg· 2025-08-29 08:24
Eli Lilly is partnering with Chinese online healthcare platform JD Health to sell its blockbuster drugs for obesity and diabetes online https://t.co/W7mYWwmpeM ...
X @Bloomberg
Bloomberg· 2025-08-06 06:00
Novo Nordisk’s earnings rose less than expected in the second quarter as the Danish drugmaker contends with competition in the crucial US market for obesity drugs https://t.co/v7F9gknCva ...
Hims Won't Back Down From Selling Cheap Weight-Loss Shots
Bloomberg Television· 2025-06-26 13:47
Sam, this is the quote that the CEO gave to our Madison Muller saying there's just no way in hell we're going to cave on that, no matter who the pharma company is or what the partnership looks like. I mean, Sam, I'm curious to hear your perspective on the fact that, I mean, his and hers is trying to stand firm here and trying to continue to sell these cheaper weight loss shots. Yes.So obviously, that's the kind of surprise or not maybe. I mean, this is a cutthroat business. There's a lot of money at stake, ...
Novo Nordisk Stock: Seems Like A No-Brainer At These Levels
Seeking Alpha· 2025-05-16 19:26
Core Viewpoint - Novo Nordisk A/S (NVO) has experienced a decline from its peak values, primarily due to the success of its obesity drugs, yet it continues to perform well in the market [1]. Group 1: Company Performance - The company is noted for its long-term investment potential, particularly in the context of its obesity drug portfolio [1]. - Novo Nordisk is characterized as a mix of growth, value, and dividend-paying stock, with a tendency towards value investments [1]. Group 2: Analyst Position - The analyst holds a beneficial long position in Novo Nordisk shares, indicating confidence in the company's future performance [2].